Kraig Biocraft Laboratories (Kraig Biocraft Laboratories) EBIT : $-2.55 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Kraig Biocraft Laboratories EBIT?

Kraig Biocraft Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kraig Biocraft Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 was -202.21%. Kraig Biocraft Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2,788.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kraig Biocraft Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.05%.

Kraig Biocraft Laboratories EBIT Historical Data

The historical data trend for Kraig Biocraft Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kraig Biocraft Laboratories EBIT Chart

Kraig Biocraft Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-2.62

-4.59

-7.39

-3.23

-2.55

Kraig Biocraft Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-0.87	-0.45	-0.47	-0.43	-1.20

Competitive Comparison of Kraig Biocraft Laboratories's EBIT

For the Specialty Chemicals subindustry, Kraig Biocraft Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kraig Biocraft Laboratories's EV-to-EBIT Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Kraig Biocraft Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kraig Biocraft Laboratories's EV-to-EBIT falls into.

Kraig Biocraft Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.55 Mil.

Kraig Biocraft Laboratories (OTCPK:KBLB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kraig Biocraft Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-4.752 * ( 1 - 0% )	/	( (2.347	+	2.353)	/ 2 )
=	-4.752	/	2.35
=	-202.21 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.627	-	6.851	-	( 2.895	-	max(0, 8.571	-	3	+	2.895	))
=	2.347

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.233	-	7.192	-	( 2.552	-	max(0, 8.886	-	2.574	+	2.552	))
=	2.353

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Kraig Biocraft Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.796	/	( ( (0.182 + max(-6.746, 0))	+	(0.162 + max(-7.17, 0)) )	/	2 )
=	-4.796	/	( ( 0.182	+	0.162 )	/	2 )
=	-4.796	/	0.172
=	-2,788.37 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.007	+	0.098)	-	(6.851	+	0	+	0)
=	-6.746

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.007	+	0.015)	-	(7.192	+	0	+	0)
=	-7.17

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kraig Biocraft Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-2.545	/	124.035
	=	-2.05 %

Kraig Biocraft Laboratories EBIT Related Terms

Thank you for viewing the detailed overview of Kraig Biocraft Laboratories's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kraig Biocraft Laboratories (Kraig Biocraft Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Kraig Biocraft Laboratories Inc (OTCPK:KBLB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2723 South State Street, Suite 150, Ann Arbor, MI, USA, 48104

Website

https://www.kraiglabs.com

Kraig Biocraft Laboratories Inc is engaged in the development of high-strength fibers using recombinant DNA technology mainly for commercial applications. It uses genetic engineering technologies to develop fibers with greater strength, resiliency, and flexibility for use in its target markets, namely the textile, specialty fiber, and technical textile industries. Its products include Monster Silk, which incorporates the natural elasticity of spider silk to make a silk fiber that is more flexible than conventional silk fibers and textiles; and Dragon Silk, which combines the elasticity of Monster Silk with additional high strength elements of native spider silk; Spydasilk; and Spydra. It generates the majority of its revenues from its business across the United States.

Executives

Jonathan Richard Rice	officer: COO	2723 S STATE STREET, SUITE 150, ANN ARBOR MI 48104
Kimberly Kraig Thompson	director, 10 percent owner, officer: CEO, CFO	2723 S STATE STREET, SUITE 150, ANN ARBOR MI 48401